Free Trial
→ INSANE DRONE FOOTAGE (From Paradigm Press) (Ad)tc pixel Free ATHE Stock Alerts

Alterity Therapeutics (ATHE) Competitors

Alterity Therapeutics logo
$3.12 0.00 (0.00%)
Closing price 10/9/2026 03:59 PM Eastern
Extended Trading
$3.12 0.00 (-0.16%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

ATHE vs. ACB, PALI, SIGA, LFCR, and CRDL

Should you buy Alterity Therapeutics stock or one of its competitors? Alterity Therapeutics's main competitors and comparable companies include Aurora Cannabis (ACB), Palisade Bio (PALI), Siga Technologies (SIGA), Lifecore Biomedical (LFCR), and Cardiol Therapeutics (CRDL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Alterity Therapeutics compare to Aurora Cannabis?

Alterity Therapeutics (NASDAQ:ATHE) and Aurora Cannabis (NASDAQ:ACB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Alterity Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 220.51%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Alterity Therapeutics is more favorable than Aurora Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alterity Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Aurora Cannabis
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Aurora Cannabis had 20 more articles in the media than Alterity Therapeutics. MarketBeat recorded 26 mentions for Aurora Cannabis and 6 mentions for Alterity Therapeutics. Aurora Cannabis' average media sentiment score of 0.27 beat Alterity Therapeutics' score of 0.26 indicating that Aurora Cannabis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alterity Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aurora Cannabis
5 Very Positive mention(s)
6 Positive mention(s)
6 Neutral mention(s)
5 Negative mention(s)
1 Very Negative mention(s)
Neutral

Alterity Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

2.1% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by company insiders. Comparatively, 0.0% of Aurora Cannabis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Alterity Therapeutics has higher earnings, but lower revenue than Aurora Cannabis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alterity TherapeuticsN/AN/A-$15.88MN/AN/A
Aurora Cannabis$247.82M1.19-$88.13M-$1.41N/A

Alterity Therapeutics has a net margin of 0.00% compared to Aurora Cannabis' net margin of -32.26%. Aurora Cannabis' return on equity of 4.37% beat Alterity Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Alterity TherapeuticsN/A N/A N/A
Aurora Cannabis -32.26%4.37%3.45%

Summary

Aurora Cannabis beats Alterity Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Alterity Therapeutics compare to Palisade Bio?

Palisade Bio (NASDAQ:PALI) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

In the previous week, Alterity Therapeutics had 2 more articles in the media than Palisade Bio. MarketBeat recorded 6 mentions for Alterity Therapeutics and 4 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.56 beat Alterity Therapeutics' score of 0.26 indicating that Palisade Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Palisade Bio
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alterity Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Alterity Therapeutics has lower revenue, but higher earnings than Palisade Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Palisade Bio$250K1,073.50-$16.78M-$0.48N/A
Alterity TherapeuticsN/AN/A-$15.88MN/AN/A

11.8% of Palisade Bio shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 0.1% of Palisade Bio shares are owned by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Palisade Bio currently has a consensus target price of $9.29, suggesting a potential upside of 502.97%. Alterity Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 220.51%. Given Palisade Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Palisade Bio is more favorable than Alterity Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Palisade Bio
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.00
Alterity Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Alterity Therapeutics' return on equity of 0.00% beat Palisade Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Palisade BioN/A -33.47% -31.79%
Alterity Therapeutics N/A N/A N/A

Palisade Bio has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

Summary

Palisade Bio beats Alterity Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Alterity Therapeutics compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

In the previous week, Alterity Therapeutics had 5 more articles in the media than Siga Technologies. MarketBeat recorded 6 mentions for Alterity Therapeutics and 1 mentions for Siga Technologies. Siga Technologies' average media sentiment score of 0.91 beat Alterity Therapeutics' score of 0.26 indicating that Siga Technologies is being referred to more favorably in the media.

Company Overall Sentiment
Siga Technologies Positive
Alterity Therapeutics Neutral

Siga Technologies has higher revenue and earnings than Alterity Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Siga Technologies$94.57M2.49$23.28M-$0.05N/A
Alterity TherapeuticsN/AN/A-$15.88MN/AN/A

Siga Technologies has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

55.4% of Siga Technologies shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 2.7% of Siga Technologies shares are held by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Alterity Therapeutics has a net margin of 0.00% compared to Siga Technologies' net margin of -5.19%. Alterity Therapeutics' return on equity of 0.00% beat Siga Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Siga Technologies-5.19% -1.55% -1.32%
Alterity Therapeutics N/A N/A N/A

Alterity Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 220.51%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Alterity Therapeutics is more favorable than Siga Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Siga Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Alterity Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Summary

Alterity Therapeutics beats Siga Technologies on 8 of the 13 factors compared between the two stocks.

How does Alterity Therapeutics compare to Lifecore Biomedical?

Lifecore Biomedical (NASDAQ:LFCR) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Alterity Therapeutics has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -29.93%.

Company Net Margins Return on Equity Return on Assets
Lifecore Biomedical-29.93% N/A -16.16%
Alterity Therapeutics N/A N/A N/A

In the previous week, Lifecore Biomedical and Lifecore Biomedical both had 6 articles in the media. Lifecore Biomedical's average media sentiment score of 0.26 beat Alterity Therapeutics' score of 0.26 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lifecore Biomedical
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alterity Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Lifecore Biomedical has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

Alterity Therapeutics has lower revenue, but higher earnings than Lifecore Biomedical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lifecore Biomedical$128.87M1.89-$40.50M-$1.07N/A
Alterity TherapeuticsN/AN/A-$15.88MN/AN/A

83.4% of Lifecore Biomedical shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 32.7% of Lifecore Biomedical shares are held by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Lifecore Biomedical currently has a consensus price target of $6.50, suggesting a potential upside of 0.78%. Alterity Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 220.51%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Alterity Therapeutics is more favorable than Lifecore Biomedical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lifecore Biomedical
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80
Alterity Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

Summary

Alterity Therapeutics beats Lifecore Biomedical on 7 of the 11 factors compared between the two stocks.

How does Alterity Therapeutics compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

In the previous week, Alterity Therapeutics had 5 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 6 mentions for Alterity Therapeutics and 1 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 1.79 beat Alterity Therapeutics' score of 0.26 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Cardiol Therapeutics Very Positive
Alterity Therapeutics Neutral

Cardiol Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 713.01%. Alterity Therapeutics has a consensus target price of $10.00, indicating a potential upside of 220.51%. Given Cardiol Therapeutics' higher probable upside, equities analysts plainly believe Cardiol Therapeutics is more favorable than Alterity Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiol Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Alterity Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiol TherapeuticsN/AN/A-$24.20M-$0.25N/A
Alterity TherapeuticsN/AN/A-$15.88MN/AN/A

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cardiol Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

Alterity Therapeutics' return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cardiol TherapeuticsN/A -180.44% -140.28%
Alterity Therapeutics N/A N/A N/A

Summary

Alterity Therapeutics beats Cardiol Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Alterity Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATHE vs. The Competition

Export
MetricAlterity TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$56.57M$12.39B$7.25B$13.28B
Dividend YieldN/A2.63%2.52%22.58%
P/E RatioN/A800.13275.5926.13
Price / SalesN/A754.43586.2786.30
Price / CashN/A15.2827.3036.12
Price / Book1.959.1510.826.16
Net Income-$15.88M$2.84B$3.50B$381.12M
7 Day Performance-3.11%-0.88%-1.19%-1.43%
1 Month Performance-22.96%-3.66%-4.00%-3.36%
1 Year Performance-27.27%-3.95%7.13%1.49%

Alterity Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATHE
Alterity Therapeutics
3.1598 of 5 stars		$3.12
flat		$10.00
+220.5%		-27.3%$56.57MN/AN/A11
ACB
Aurora Cannabis
1.116 of 5 stars		$4.03
-1.5%		N/A-15.3%$265.20M$314.07MN/A1,028
PALI
Palisade Bio
2.1429 of 5 stars		$1.45
-3.3%		$9.83
+578.2%		-23.0%$261.41M$250KN/A14
SIGA
Siga Technologies
0.2783 of 5 stars		$3.44
-0.6%		N/A-60.1%$247.16M$53.66MN/A49
LFCR
Lifecore Biomedical
1.1631 of 5 stars		$6.59
+1.1%		$6.50
-1.4%		-0.8%$246.80M$128.87MN/A382

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ATHE) was last updated on 10/12/2026 by MarketBeat.com Staff.
From Our Partners
Palantir and Wall Street are in on it…
Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has pou...
Monument Traders Alliance | Sponsoredtc pixel
Urgent Attention to Executive Order #14363 (Buy This Stock Before Oct. 20th
Marc Chaikin, a 60-year Wall Street veteran whose past clients include George Soros and Steve Cohen, built a s...
Chaikin Analytics | Sponsoredtc pixel
Urgent: Invest In ‘Elon’s iPhone’ Before July 22nd
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Federal Reserve Reveals Disturbing New Plan To Control Your Money
Docket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...
Weiss Ratings | Sponsoredtc pixel
Five Seats Could Shift Washington’s Direction
Democrats need just five more seats to flip House control, with forecasts giving them a 61% to 85% chance ahea...
USA Capital Gold | Sponsoredtc pixel
Trump To Relaunch USD?
President Trump's summit with Xi Jinping drew headlines for tariffs and trade truces, but the real story may b...
Porter & Company | Sponsoredtc pixel